Pulmonary Arterial Hypertension Associated With Calcitonin Gene-Related Peptide Antagonist Therapy for Migraine
CHEST · 2026-06 · 169 (6) · e175-e179
DOI: 10.1016/j.chest.2025.12.032 ↗Kurz gefasst
Fallbericht in der Zeitschrift CHEST, 2026-06. Verfasst von Kimberly Lu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Seattle, WA. Hauptthemen laut MEDLINE: Migraine Disorders, Calcitonin Gene-Related Peptide, Calcitonin Gene-Related Peptide Receptor Antagonists, Pulmonary Arterial Hypertension. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Calcitonin gene-related peptide (CGRP)-targeted therapies are a recent addition to the migraine field. Monoclonal antibodies became available in 2018 and gepants in 2020, both now widely used for migraine prevention and acute treatment. CGRP is also a potent endogenous pulmonary vasodilator, and its blockade worsens pulmonary hypertension in experimental models. Yet the cardiopulmonary risks of CGRP pathway inhibition in humans have not been studied systematically. We report 3 patients with hemodynamically confirmed pulmonary arterial hypertension (PAH) diagnosed while they were receiving CGRP-targeted therapy. Two patients lacked traditional PAH risk factors; the third patient had suspected portal hypertension. All patients presented with markedly elevated pulmonary vascular resistance, and 2 patients improved after CGRP-targeted therapy was discontinued and PAH treatment was initiated. Although causality cannot be inferred from these cases, the temporal association and biologic plausibility suggest a potential safety signal deserving of further study. Clinicians should remain vigilant for cardiopulmonary symptoms in patients receiving CGRP-targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Seattle, WA.
- Department of Neurology, Seattle, WA.
- Department of Medicine, Division of Cardiology, Seattle, WA.
- Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Seattle, WA; Department of Epidemiology, University of Washington, Seattle, WA.
- Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Seattle, WA; Center for Lung Biology, University of Washington, Seattle, WA. Electronic address: srayner@uw.edu.
Zitieren
APA
Lu, K., Barros, L. M., Murinova, N., Buber, J., Leary, P. J., & Rayner, S. G. (2026). Pulmonary Arterial Hypertension Associated With Calcitonin Gene-Related Peptide Antagonist Therapy for Migraine. CHEST, 169(6), e175-e179. https://doi.org/10.1016/j.chest.2025.12.032
Vancouver
Lu K, Barros LM, Murinova N, Buber J, Leary PJ, Rayner SG. Pulmonary Arterial Hypertension Associated With Calcitonin Gene-Related Peptide Antagonist Therapy for Migraine. CHEST. 2026;169(6):e175-e179. doi:10.1016/j.chest.2025.12.032
BibTeX
@article{Lu2026,
author = {Lu, Kimberly and Barros, Lia M and Murinova, Natalia and Buber, Jonathan and Leary, Peter J and Rayner, Samuel G},
title = {Pulmonary Arterial Hypertension Associated With Calcitonin Gene-Related Peptide Antagonist Therapy for Migraine},
journal = {CHEST},
year = {2026},
volume = {169},
number = {6},
pages = {e175--e179},
doi = {10.1016/j.chest.2025.12.032}
}
EUVIMED